The RBC membrane nanocarrier group significantly inhibited the production of inflammatory cytokines such as TNF-α and IL-6 and the expression of IL-1β and caspase-1 in the lung tissue of ALI/ARDS and prolonged the drug release time (Ding et al., 2022). Here, IL1B is linked to acute respiratory distress syndrome.